What Researchers Did
Researchers conducted a systematic review of 45 individual case reports and 18 case series published between 2000 and March 2020, focusing on cerebral mucormycosis in diabetic patients.
What They Found
The review found an overall mortality rate of 46.3% in individual cases, which increased to 64.2% in patients with diabetic ketoacidosis. Common symptoms included facial swelling (53.3%), headache (44.4%), and vision loss (35.5%). While 91.1% of patients underwent surgery and all received Amphotericin B, hyperbaric oxygen therapy (HBOT) was used in combination for a number of patients.
What This Means for Canadian Patients
Cerebral mucormycosis is a severe and rapidly progressing infection, especially for diabetic patients, carrying high risks of illness and death. While surgery and antifungal medications are primary treatments, this review notes HBOT was used as an additional therapy for some patients, suggesting it could be considered in complex cases. Early diagnosis and aggressive treatment are crucial for improving outcomes.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This systematic review relied on case reports and case series, which provide less robust evidence than larger, controlled studies.